Q-omics provides the consensus-scored TSPAN11 profile across patient tissues and cancer cell-line models. TSPAN11 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TSPAN11 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, TSPAN11 RNA expression shows 17,266 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, BLCA, and TGCT as cancer lineages where TSPAN11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPAN11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPAN11 survival associations across molecular data types. TSPAN11 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPAN11 RNA expression–survival associations across cancer types. High TSPAN11 expression shows unfavorable associations in MESO and ACC, but favorable associations in HNSC, LUAD, COAD and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TSPAN11 RNA expression.
This table summarizes TSPAN11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TSPAN11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPAN11 shows lower tumor expression in BLCA, THCA, COAD, BRCA and LIHC and higher tumor expression in HNSC. The BLCA box plot shows higher TSPAN11 RNA expression in normal versus tumor tissue (log2 FC = −1.256, t-test p < 0.001).
This table shows molecular features associated with TSPAN11 in patient tissues and cancer cell lines. In patient samples, TSPAN11 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPAN11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
